Press
Press inquiries: press@nightboxllc.com
One-line description
Nightbox LLC — Wyoming-зарегистрированный, Santa Monica federal contractor (SAM UEI UHCAB6UXXKF2, CAGE 20BA7), shipping три deep-tech pillar (NKG2D-LIF6 gene therapy, UniGPU compute runtime, SilverDuck local-first AI agent), operating под Liaison Framework v2.3 bilateral US↔RF editorial doctrine.
Boilerplate paragraph (long-form)
NIGHTBOX LLC — Wyoming-formed federal contractor (SAM.gov UEI UHCAB6UXXKF2 · Active с 2026-05-18 · CAGE Code 20BA7 · EIN 39-4373044), operating из Санта-Моники, Калифорния. Founded февраль 2026 sole-member Артёмом Шакиным. Три product pillar: (1) NKG2D-LIF6 chimeric gene therapy для solid tumor oncology — provisional patent filed; (2) UniGPU vendor-neutral GPU runtime в Rust — 47.31 TFLOP/s WMMA sustained на consumer AMD RX 7700; (3) SilverDuck local-first AI agent stack с hybrid post-quantum encrypted cloud-LLM handoff (X25519 + ML-KEM-1024 + AES-256-GCM, FIPS 203 + FIPS 197). Operating posture: Liaison Framework v2.3 — двусторонняя editorial доктрина US↔РФ. Section 889 compliant. NIST 800-171 self-attested. CMMC 2.0 Level 1 self-attested. OMB M-22-09 Zero Trust. Apache 2.0 + CC-BY-4.0 open source. Pre-seed stage.
Factsheet
| Founded | Февраль 2026 |
| Headquarters | Вайоминг (incorporated) · район Лос-Анджелеса (operations) |
| Founder & CEO | Артём Шакин |
| Отрасль | Biotechnology · Gene Therapy · Vendor-Neutral GPU Compute · Local-First AI |
| Stage | Pre-seed |
| Lead asset | NKG2D-LIF6 chimeric receptor-effector (2,123 bp) |
| Indication | Solid tumor oncology (CRC, melanoma, pancreatic — initial) |
| Modality | AAV9-delivered single-construct gene therapy |
| EIN | 39-4373044 |
| SAM UEI | UHCAB6UXXKF2 (Active) |
| CAGE Code | 20BA7 (DLA Battle Creek, 2026-05-17) |
Story angles
- Solo-founder biotech, using AI agent infrastructure как core R&D — modern minimalist company structure
- Comparative cancer biology applied directly: encoding elephant LIF6 mechanism в therapeutic
- Bypassing CAR-T manufacturing bottleneck через single-construct gene therapy
- Clean IP whitespace на specific NKG2D-LIF6 chimera (zero prior art на combination)
- Wyoming legal structure + Лос-Анджелес operations — emerging hub outside Boston/Bay Area
- Russian-American founder, editorial Liaison Framework — двусторонняя editorial doctrine US↔RF, anti-state-capture симметрично, transparent business-liaison architecture
- Market Re-Entry Roadmap — 14+ западных компаний maintaining IP в Rospatent через 2025: leading indicator анализ для US policy + corporate-strategy desks
Доступные цитаты
Артём Шакин (Founder & CEO) available для interviews по cancer biology, comparative oncology, AI-augmented biotech operations, NKG2D-LIF6 platform, US↔RF bilateral editorial doctrine и Market Re-Entry analysis. Контакт: press@nightboxllc.com.